| Literature DB >> 17570844 |
Zheng Li1, Shireesh Srivastava, Sheenu Mittal, Xuerui Yang, Lufang Sheng, Christina Chan.
Abstract
BACKGROUND: The ability to obtain profiles of gene expressions, proteins and metabolites with the advent of high throughput technologies has advanced the study of pathway and network reconstruction. Genome-wide network reconstruction requires either interaction measurements or large amount of perturbation data, often not available for mammalian cell systems. To overcome these shortcomings, we developed a Three Stage Integrative Pathway Search (TIPS(c)) approach to reconstruct context-specific active pathways involved in conferring a specific phenotype, from limited amount of perturbation data. The approach was tested on human liver cells to identify pathways that confer cytotoxicity.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17570844 PMCID: PMC1906836 DOI: 10.1186/1471-2105-8-202
Source DB: PubMed Journal: BMC Bioinformatics ISSN: 1471-2105 Impact factor: 3.169
Figure 1Cytotoxicity (LDH release). Confluent HepG2 cells exposed to different types of fatty acids (0.7 mM, complexed to 4% w/v BSA) and TNF-α for 24 and 48 hours. X-axis labels indicate the TNF-α concentration in ng/ml and the medium employed in each condition. Data expressed as averages of nine samples +/- s.d. from three independent experiments. a, Significant medium effect, P < 0.05 relative to control (BSA medium with no TNF-α); b, Significant TNF-α effect within a treatment, P < 0.05 compared to corresponding medium with no TNF-α exposure. TNF-α concentrations are in ng/ml.
Figure 2Intracellular TG accumulation. Intracellular TG accumulation increased in FFA treated cells. * significantly higher than control, p < 0.01 by t-test. H: control, P: palmitate treatment, O: oleate treatment, L: linoleate treatment.
Functional groups of genes related to LDH release, selected by GA/PLS
| (gC) cytochrome P450, polypeptide 1 (CYP1A1) | 12 | ||
| (g) glutamate-cysteine ligase, catalytic subunit | 11 | ||
| (gC) NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1 | 10 | ||
| (gC) glutathione S-transferase A2 (GSTA2) | 10 | ||
| (gC) P450 (cytochrome) oxidoreductase (POR) | 10 | ||
| (gC) glutathione S-transferase theta 1 (GSTT1) | 10 | ||
| (gC) NADH dehydrogenase (ubiquinone) 1 | 9 | ||
| (gC) ATP synthase, H+ transporting, subunit c | 8 | ||
| (gC) glutaredoxin (thioltransferase) (GLRX) | 8 | ||
| (gC) glutathione reductase (GSR) | 8 | ||
| (gC) glutathione S-transferase M3 | 8 | ||
| (gC) glutathione peroxidase 3 (plasma) (GPX3) | 7 | ||
| (gC) metallothionein 1G (MT1G) | 7 | ||
| (gC) NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10 | 7 | ||
| (gC) cytochrome c (HCS) | 7 | ||
| (gC) cytochrome P450, subfamily XXIV (CYP24) | 7 | ||
| (gC) NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 | 7 | ||
| (gK) cytochrome P450, polypeptide 7 (CYP2A7) | 7 | ||
| (gM) holocytochrome c synthase (HCCS) | 7 | ||
| (gM) NAD(P)H dehydrogenase, quinone 2 (NQO2), mRNA | 7 | ||
| (gC) microsomal glutathione S-transferase 2 (MGST2) | 7 | ||
| (gC) cytochrome P450, subfamily IVF, polypeptide 12 (CYP4F12) | 7 | ||
| (gC) isocitrate dehydrogenase 2 (NADP+), mitochondrial (IDH2) | 12 | ||
| (gC) citrate synthase (CS) | 8 | ||
| (gC) succinate-CoA ligase, GDP-forming, beta subunit | 7 | ||
| (g) nuclear factor I/X (CCAAT-binding transcription factor) (NFIX) | 12 | ||
| (gC) zinc finger protein 36, C3H type-like 1 (ZFP36L1) | 9 | ||
| (gC) inhibitor of kappa light polypeptide gene enhancer in B-cells | 7 | ||
| (gC) TRAF family member-associated NFκβ activator (TANK) | 9 | ||
| (gC) lymphotoxin alpha (TNF- superfamily, member 1) (LTA) | 9 | ||
| (gC) Fas (TNF-RSF6) associated factor 1 (FAF1) | 8 | ||
| (gC) tumor necrosis factor (ligand) superfamily, member 13 (TNF-SF13) | 8 | ||
| (gC) LPS-induced TNF-alpha factor (PIG7) | 8 | ||
| (gC) Fas (TNF-RSF6)-associated via death domain (FADD) | 7 | ||
| (g) tumor necrosis factor, alpha-induced protein 3 (TNF-AIP3) | 7 | ||
| (gK) tumor necrosis factor receptor superfamily, member 5 (TNF-RSF5) | 7 | ||
| (gC) TNF-AIP3 interacting protein 2 (TNIP2) | 7 | ||
| (gC) TNF-AIP3 interacting protein 1 (TNIP1) | 7 | ||
| (gC) TNF- receptor-associated factor 1 (TRAF1) | 7 | ||
| (gC) tumor necrosis factor, alpha-induced protein 1 (TNF-AIP1) | 7 | ||
| (gC) tumor necrosis factor (ligand) superfamily, member 9 (TNF-SF9) | 7 | ||
| (gC) S100 calcium binding protein P (S100P) | 12 | ||
| (gC) protein phosphatase 4, regulatory subunit 1 (PPP4R1) | 10 | ||
| (gC) protein tyrosine kinase 9 (PTK9) | 10 | ||
| (gC) protein phosphatase 1, regulatory (inhibitor) subunit 15B | 10 | ||
| (gM) solute carrier family 38, member 2 (SLC38A2) | 10 | ||
| (gM) protein kinase C substrate 80K-H (PRKCSH) | 10 | ||
| (g) tumor-associated calcium signal transducer 2 (TACSTD2) | 10 | ||
| (gC) serine/threonine kinase 17a (apoptosis-inducing) (STK17A) | 9 | ||
| (gC) MAP kinase-interacting serine/threonine kinase 2 (MKNK2) | 9 | ||
| (gC) mitogen-activated protein kinase 6 | 9 | ||
| (gC) phospholipase A2, group IVB (cytosolic) | 9 | ||
| (gC) insulin-like growth factor binding protein 1 (IGFBP1) | 9 | ||
| (gM) protein tyrosine phosphatase, receptor type, N (PTPRN) | 8 | ||
| (gN) G protein-coupled receptor 87 (GPR87) | 8 | ||
| (gC) serine/threonine kinase 17a (apoptosis-inducing) (STK17A) | 8 | ||
| (gC) mitogen-activated protein kinase 3 | 8 | ||
| (gM) G protein-coupled receptor 48 (GPR48) | 8 | ||
| (gM) protein phosphatase 1, regulatory (inhibitor) subunit 12A (PPP1R12A) | 8 | ||
| (gC) mitogen-activated protein kinase kinase kinase 7 | 8 | ||
| (gM) protein phosphatase 1, regulatory (inhibitor) subunit 11 (PPP1R11) | 8 | ||
| (gC) cyclin-dependent kinase (CDC2-like) 10 (CDK10) | 8 | ||
| (gC) potassium inwardly-rectifying channel, subfamily J, member 2 (KCNJ2) | 8 | ||
| (gC) mitogen-activated protein kinase kinase 1 (MAP2K1) | 8 | ||
| (gM) phospholipase C, delta 4 (PLCD4) | 7 | ||
| (gC) protein kinase C, delta | 7 | ||
| (gC) protein phosphatase 1, catalytic subunit, alpha isoform (PPP1CA) | 7 | ||
| (gC) protein kinase C binding protein 1 | 7 | ||
| (gC) protein phosphatase 2 (formerly 2A), catalytic subunit | 7 | ||
| (gC) MAP3K7IP1 | 7 | ||
| (gC) serine/threonine kinase 6 (STK6) | 7 | ||
| (gC) protein tyrosine phosphatase, receptor type, K (PTPRK) | 7 | ||
| (gC) MAP4K2 | 7 | ||
| (gC) G protein-coupled receptor kinase 5 (GPRK5) | 7 | ||
| (gC) protein tyrosine phosphatase, receptor type, N polypeptide 2 (PTPRN2) | 7 | ||
| (gC) fatty acid amide hydrolase (FAAH) | 12 | ||
| (gC) fatty-acid-Coenzyme A ligase, long-chain 3 (FACL3) | 9 | ||
| (gC) long-chain fatty-acyl elongase (LCE) | 7 | ||
| (gC) fatty acid amide hydrolase | 7 | ||
| (gC) BCL2/adenovirus E1B 19kDa interacting protein 3 (BNIP3) | 10 | ||
| (gN) caspase 6, apoptosis-related cysteine protease (CASP6) | 10 | ||
| (gC) acid sphingomyelinase-like phosphodiesterase (ASM3A) | 9 | ||
| (gC) caspase 8, apoptosis-related cysteine protease (CASP8) | 8 | ||
| (gC) caspase 10, apoptosis-related cysteine protease (CASP10) | 8 | ||
| (gF) requiem, apoptosis response zinc finger gene (REQ) | 8 | ||
| (gC) UDP-glucose ceramide glucosyltransferase | 7 | ||
| (gC) sphingosine kinase 2 (SPHK2) | 7 | ||
| (gC) programmed cell death 5 (PDCD5) | 7 | ||
| (gC) sphingosine-1-phosphate lyase 1 | 7 | ||
| (gC) BCL2-like 13 (apoptosis facilitator) (BCL2L13) | 7 | ||
| (gM) eukaryotic translation termination factor 1 (ETF1) | 10 | ||
| (gC) eukaryotic translation initiation factor 2, subunit 2 beta, 38kDa (EIF2S2) | 10 | ||
| (gC) translational inhibitor protein p14.5 (UK114) | 8 | ||
| (gC) eukaryotic translation initiation factor 3, subunit 10 theta | 8 | ||
| (gC) eukaryotic translation initiation factor 4 gamma, 3 (EIF4G3) | 7 | ||
| (gC) eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa (EIF2B2) | 8 | ||
| (gC) translocase of outer mitochondrial membrane 34 (TOMM34) | 10 | ||
| (gC) translocase of inner mitochondrial membrane 22 homolog (yeast) (TIMM22) | 9 | ||
| (gM) translocase of outer mitochondrial membrane 20 | 7 | ||
Figure 3Caspase activity. Palmitate treatment increased caspase-3 activity significantly as compared to control (BSA) and unsaturated fatty acid (oleate). * significantly higher in palmitate, p < 0.01 by t-test. BSA: control, Ole: oleate treatment, Palm: palmitate treatment.
Figure 4Network reconstructed with constraints based algorithm. GA/PLS and ICA selected the relevant genes, and BN analysis reconstructed the network using the selected subset of genes. The network provides an overview of the factors and pathways involved in regulating cytotoxicity. The nodes discussed in the paper are highlighted in red. Microsoft Visio was used to generate the Figure.
Figure 5Effect of palmitate on stearoyl-CoA desaturase (SCD) measured by western blotting. (A) SCD was downregulated in the palmitate (0.7 mM) cultures as compared to the oleate (0.7 mM) and control cultures. (B) Co-supplementation of oleate (0.3 mM) with palmitate (0.4 mM) prevented the downregulation of SCD. (C) Co-supplementing palmitate (0.4 mM) with oleate (0.3 mM) decreased LDH release significantly, P < 0.01 (t-test). P: treated with 0.7 mM palmitate for 48 hours, PO: treated with 0.4 mM palmitate plus 0.3 mM oleate for 48 hours. Data expressed as average +/- SD from three independent experiments, * significantly lower than palmitate, p < 0.01 by t-test.
Simulating genetic perturbation and its effects on LDH release
| SCD | low | 0.33 | 0.67 |
| high | 0.65 | 0.35 ↓ | |
| NF-KB | low | 0.47 | 0.53 |
| high | 0.77 | 0.23↓ | |
| PKR | low | 0.65 | 0.25↓ |
| high | 0.57 | 0.43 | |
The probability of LDH release taking on a high or low level in the palmitate cultures. BN inference was used to conduct the simulations of up-regulation of SCD, down-regulation of PKR, and up-regulation of NF-KB. "↓" indicates decreased probability and "↑" indicates increased probability.
Figure 6Effect of SCD activators clofibrate and ciprofibrate on LDH release in the palmitate cultures. Clofibrate and ciprofibrate are known to transcriptionally increase the activity of SCD. Palm: treated with 0.7 mM palmitate for 48 hours, Palm+clofibrate: treated with 50 μM clofibrate and 0.7 mM palmitate, Palm+ciprofibrate: treated with 50 μM ciprofibrate and 0.7 mM palmitate. 6 hours pretreatment followed by 48 hours co-supplementation of 50 μM of clofibrate or ciprofibrate significantly decrease LDH release in the palmitate culture, P < 0.01 (t-test). Data expressed as average +/- SD from three independent experiments, * significantly lower than in control, p < 0.01 by t-test. H: control, P: palmitate treatment, O: oleate treatment, P+O: palmitate and oleate co-supplementation.
Figure 7Effect of palmitate and TNF-α on Bcl-2 expression measured by western blotting. (A) TNF-α supplementation at 20–100 ng/ml downregulated Bcl-2 in the control, palmitate, and oleate cultures. Similarly, palmitate downregulated Bcl-2 protein expression level as compared to the control and oleate cultures. (B) Effect of PKR inhibition on Bcl-2 level in the palmitate cultures. PKR inhibitor (6 μM) increased the expression of Bcl-2 in palmitate cultured cells.
Simulating down-regulation of PKR and its effects on Bcl-2
| high | 0.55 | 0.45 | |
| PKR | low | 0.44 | 0.56 ↑ |
The probability of Bcl-2 taking on a high or low level in the palmitate cultures. BN inference was used to conduct the simulations of down-regulation of PKR. "↓" indicates decreased probability and "↑" indicates increased probability. This was validated experimentally as shown in Figure 7.
Figure 8Phosphorylated p65 subunit of NF-kB was determined by western blot with a monoclonal antibody. 1) HepG2, 2) TNF-α at 20 ng/m; 3) TNFα at 100 ng/ml; 4) BSA 5) BSA+TNF-α at 20 ng/ml; 6) BSA+TNF-α at 100 ng/ml; 7) palmitate; 8) palmitate + TNF-α at 20 ng/ml; 9) palmitate + TNF-α at 100 ng/ml.
Simulating down-regulation of PKC-δ and its effects on NF-κβ.
| high | 0.39 | 0.61 | |
| PKC-δ | low | 0.51 | 0.49 ↓ |
The probability of NF-κβ taking on a high or low level. The model predicts that a down-regulation in PKC-δ will decrease the probability of NF-κβ taking on a high value. This was validated experimentally and shown in Figure 9. "↓" indicates decreased probability and "↑" indicates increased probability.
Figure 9Effect of rottlerin on NF-κB measured by western blotting. Expression of phospho-P65 NF-κB in control and palmitate mediums with 0, 20, 100 ng/ml TNF-α, gith and without rottlerin (5 μM). TNF-α activated phospho-P65 NF-κB and this activation was attenuated with the PKC-δ inhibitor, rottlerin.
Figure 10The framework to integrate gene expression and metabolic profiles. The relevancy of each gene to LDH release was first evaluated with GA/PLS. Genes with higher frequencies were considered to be more relevant. The frequencies and profile of the LDH release were then used to constrain the ICA model to extract an independent component that represents the cellular process. The genes in the independent component with high coefficients were subjected to BN analysis.